Compare SCKT & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCKT | XRTX |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.9M |
| IPO Year | 1996 | 2018 |
| Metric | SCKT | XRTX |
|---|---|---|
| Price | $0.53 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 166.0K | ★ 407.3K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,078,332.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.35 |
| 52 Week High | $2.79 | $3.60 |
| Indicator | SCKT | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 44.11 |
| Support Level | $0.38 | $0.39 |
| Resistance Level | $0.99 | $2.29 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 26.53 | 29.24 |
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the United States, Europe, Asia and Rest of the world, of which the majority of the revenue is generated from the United States.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.